Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029951 | PMC |
| http://dx.doi.org/10.1111/jch.13976 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.
Nat Commun
September 2024
Axe Cancer, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Article Synopsis
- A study found that antibiotics can harm the good bacteria in our bodies and make cancer treatments less effective, particularly a type of treatment called immune checkpoint inhibitors (ICI).
- Researchers tested a new treatment called DAV132 on healthy volunteers to see if it could help fix the issues caused by antibiotics, and it turned out to be safe and did not change antibiotic levels too much.
- In mice tests, DAV132 helped keep the good bacteria safe and improved the effectiveness of cancer treatments compared to those given antibiotics alone. This means DAV132 might be a good way to protect the bacteria and help cancer patients who take antibiotics.
Comprehensive mapping of immune perturbations associated with aplastic anemia.
Cell Biol Toxicol
September 2024
Department of Hematology, Guangzhou First People's Hospital, Guangzhou, 510180, China.
Background: Aplastic anemia (AA) is an immune-mediated syndrome characterized by bone marrow failure. Therefore, comprehending the cellular profile and cell interactions in affected patients is crucial.
Methods: Human peripheral blood mononuclear cells (PBMCs) were collected from both healthy donors (HDs) and AA patients, and analyzed using multicolor flow cytometry.
Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.
J Eur Acad Dermatol Venereol
September 2024
Inflammation & Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA.
Both alopecia areata (AA) and vitiligo share common pathogenesis involving, interferon-γ (IFN-γ) and interleukin-15 (IL-15) signalling pathways that activate cytotoxic CD8+ T lymphocytes. These shared mechanisms may explain why both diseases respond to currently available treatments (e.g.
View Article and Find Full Text PDFBiomodulatory Effects of Molecular Delivery in Human T Cells Using 3D-Printed Acoustofluidic Devices.
Ultrasound Med Biol
November 2024
Department of Bioengineering, University of Louisville, Louisville, KY, USA. Electronic address:
Objective: Cell-based therapies have shown significant promise for treating many diseases, including cancer. Current cell therapy manufacturing processes primarily utilize viral transduction to insert genomic material into cells, which has limitations, including variable transduction efficiency and extended processing times. Non-viral transfection techniques are also limited by high variability or reduced molecular delivery efficiency.
View Article and Find Full Text PDFA Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant, Results of a Prospective Trial.
Transplant Cell Ther
October 2024
Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address:
Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative treatment for many hematologic malignancies (HM). We previously developed a two-step approach that separates the lymphoid and myeloid portions of the graft, allowing a consistent T cell dosing and sparing the stem cells from the effect of post-transplant cyclophosphamide (CY). The two-step approach demonstrated safety and efficacy in patients treated with myeloablative and reduced-intensity conditioning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!